Tenpoint Therapeutics Submits New Drug Application to Health Canada for Adult Presbyopia Treatment

Tenpoint Therapeutics Submits New Drug Application to Health Canada for YUVEZZI Eye Drops to Treat Presbyopia in Adults

Tenpoint Therapeutics, a global commercial ophthalmic pharmaceutical company focused on developing innovative treatments to improve vision in the aging eye, announced that it has submitted an NDS to Health Canada for the review and potential approval of YUVEZZI. The investigational ophthalmic solution combines carbachol and brimonidine tartrate at concentrations of 2.75% and 0.1%, respectively.

The proposed treatment is designed to address presbyopia, a common age-related vision condition that affects the ability to focus on nearby objects. The once-daily combination eye drop is intended to provide adults with an alternative treatment option for managing difficulties associated with close-up vision.

The regulatory submission follows encouraging clinical findings from two Phase 3 randomized, double-masked, controlled studies, known as BRIO I and BRIO II. According to the company, these studies demonstrated that YUVEZZI significantly improved near vision with one daily drop.

The clinical findings also showed that the treatment achieved miosis, or pupil constriction, beginning 30 minutes after administration and lasting for up to 10 hours. In addition, YUVEZZI was reported to be well tolerated in the clinical program, with no treatment-related serious adverse events observed across more than 72,000 dosing days monitored in the BRIO II study.

The submission to Health Canada represents another step in Tenpoint Therapeutics’ efforts to make YUVEZZI available to patients in additional international markets. If approved, the treatment could provide Canadian adults experiencing presbyopia with another option for addressing near-vision difficulties and reducing their dependence on reading glasses for certain everyday activities.

Presbyopia Represents a Significant Global Vision Care Challenge

Presbyopia is a progressive, age-related condition characterized by the gradual loss of the eye’s ability to focus on nearby objects. It commonly begins around the age of 45 and affects approximately 2 billion people worldwide.

The condition develops as the natural lens inside the eye gradually loses flexibility, making it increasingly difficult to adjust focus when looking at objects at different distances.

In younger individuals, the eye’s natural lens can change shape to focus on nearby objects. This process, known as accommodation, allows people to perform activities such as reading, writing, using smartphones, and viewing objects at close range.

As people age, the lens becomes less flexible, reducing its ability to adjust focus. Consequently, individuals may begin experiencing blurred near vision and difficulty performing tasks that require sustained close-up visual attention.

Presbyopia can affect several aspects of everyday life. Activities such as reading text messages, viewing restaurant menus, checking product labels, reading books, working on computers, and completing other routine tasks may become increasingly challenging.

Many individuals manage the condition using reading glasses, bifocals, progressive lenses, or other corrective vision solutions. Although these approaches can help improve near vision, some people find it inconvenient to repeatedly search for, carry, or switch between different pairs of glasses throughout the day.

The growing global population affected by presbyopia has created demand for additional treatment approaches that can improve near vision and support daily activities.

Tenpoint Therapeutics is developing YUVEZZI as a pharmaceutical treatment option for adults with presbyopia. The company’s approach focuses on combining two active ingredients in a single ophthalmic formulation designed for once-daily administration.

By pursuing regulatory approval in Canada, Tenpoint aims to expand the availability of its ophthalmic product portfolio and provide another potential treatment option for people experiencing age-related vision changes.

YUVEZZI Combines Carbachol and Brimonidine in a Once-Daily Formulation

YUVEZZI is a dual-agent ophthalmic solution containing carbachol 2.75% and brimonidine tartrate 0.1%.

The formulation combines two active pharmaceutical ingredients with complementary pharmacological properties. The treatment is designed to improve near vision through its effects on the pupil.

Carbachol is a cholinergic agent that acts on muscarinic receptors and can produce pupil constriction. This effect is known as miosis.

Pupil constriction can increase the eye’s depth of focus, helping improve the ability to see objects at close distances. This mechanism is particularly relevant in presbyopia because reduced accommodation makes it more difficult for the eye to focus on nearby objects.

Brimonidine tartrate is an alpha-2 adrenergic receptor agonist used in ophthalmology. In the YUVEZZI formulation, it is combined with carbachol as part of the company’s dual-agent approach to presbyopia management.

The combination is intended to provide a treatment option that can be administered once daily, potentially simplifying the treatment routine for adults who experience near-vision difficulties.

The formulation’s clinical development has focused on evaluating improvements in near visual acuity, the duration of pupil constriction, and overall tolerability.

According to Tenpoint Therapeutics, the Phase 3 clinical findings support the potential of YUVEZZI as a once-daily treatment for adults with presbyopia.

The company is now seeking Health Canada’s assessment of the available clinical and regulatory information to determine whether the product meets the requirements for marketing authorization in Canada.

Health Canada Submission Supported by Two Phase 3 Clinical Studies

The NDS for YUVEZZI is supported by positive results from two Phase 3 clinical trials, BRIO I and BRIO II.

Both studies were randomized, double-masked, and controlled investigations designed to evaluate the treatment’s performance in individuals with presbyopia.

Randomized controlled clinical trials are an important part of pharmaceutical development because they help researchers assess the safety and effectiveness of investigational treatments under structured clinical conditions.

The double-masked design also helps reduce potential bias during the evaluation of treatment outcomes.

Across the BRIO I and BRIO II studies, YUVEZZI demonstrated significant improvements in near vision following administration of one drop once daily.

The findings are important because the treatment is intended to address a condition that can interfere with routine activities and affect the quality of life of adults as they age.

In addition to improvements in near vision, the clinical program evaluated the effects of YUVEZZI on pupil size and the duration of miosis following administration.

According to the reported findings, the treatment achieved pupil constriction beginning 30 minutes after administration, with the effect maintained for up to 10 hours.

The observed duration of miosis provides information about the treatment’s pharmacological activity throughout the day and supports the company’s once-daily dosing approach.

The results from both Phase 3 studies form the clinical foundation of the Canadian regulatory submission.

Clinical Safety Profile Demonstrates Favorable Tolerability

Safety and tolerability are important considerations in the development of ophthalmic treatments, particularly products intended for repeated daily administration.

The BRIO II clinical study included more than 72,000 monitored dosing days, providing an extensive exposure period for evaluating the treatment’s safety profile.

According to Tenpoint Therapeutics, YUVEZZI was well tolerated in the study, and no treatment-related serious adverse events were observed across the monitored dosing days.

This finding represents an important component of the clinical evidence supporting the company’s regulatory submission.

The assessment of adverse events, tolerability, and other safety parameters is essential for determining whether an ophthalmic treatment can be used appropriately in the intended patient population.

The absence of treatment-related serious adverse events in the reported BRIO II exposure data is encouraging. However, the complete safety profile, including the frequency and nature of other adverse events, will need to be considered as part of Health Canada’s regulatory review.

The regulatory authority will evaluate the clinical evidence and supporting documentation to determine whether YUVEZZI demonstrates an acceptable benefit-risk profile for the proposed indication.

Tenpoint Therapeutics Highlights Commitment to International Expansion

Commenting on the Canadian regulatory submission, Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics, emphasized the company’s commitment to expanding access to YUVEZZI and bringing the treatment to patients in additional international markets.

“Our submission of YUVEZZI to Health Canada demonstrates our continued ambition to bring this treatment to patients around the world. For many Canadians, having to search for reading glasses to do routine tasks like reading a text message, viewing a menu or working on a computer can have a frustrating impact on daily life,” Bjarke said.

He added that the submission brings the company closer to potentially offering Canadian patients an innovative treatment option designed to help them see more clearly and participate more confidently in everyday activities.

The CEO’s comments highlight the practical impact of presbyopia and the importance of developing treatment options that address the everyday visual challenges associated with the condition.

For many adults, the gradual loss of near vision can affect professional responsibilities, personal activities, and independence in routine situations.

Although reading glasses remain a widely used solution, pharmaceutical approaches such as YUVEZZI are being developed to provide additional options for managing the condition.

Tenpoint Therapeutics is seeking to advance its ophthalmic development strategy by pursuing regulatory authorization in markets where there is an opportunity to address unmet needs in vision care.

The Canadian submission represents an important step in this international strategy and follows the company’s clinical development activities evaluating the efficacy and safety of its combination eye drop.

Potential Benefits for Adults Living with Presbyopia

If approved by Health Canada, YUVEZZI could offer Canadian adults another treatment option for managing presbyopia.

The product’s once-daily administration is intended to provide a convenient approach to treatment compared with solutions that require frequent use or adjustments throughout the day.

Its dual-agent formulation is designed to improve near vision through pupil-related mechanisms, with clinical studies demonstrating significant improvements in near vision and miosis lasting up to 10 hours.

For individuals who regularly experience difficulty reading small text, using digital devices, or completing close-up tasks, improvements in near vision could potentially support greater convenience in everyday activities.

The treatment may also expand the range of pharmaceutical options available to healthcare professionals managing patients with age-related vision impairment.

However, individual treatment decisions will depend on regulatory approval, the product’s final approved labeling, patient characteristics, and the assessment of an eye care professional.

The potential availability of YUVEZZI would also add another development to the evolving presbyopia treatment landscape, where pharmaceutical companies are exploring alternatives to conventional corrective lenses.

Next Steps in the Canadian Regulatory Review

Following the submission of the NDS, Health Canada will review the application and evaluate the clinical, safety, quality, and manufacturing information provided by Tenpoint Therapeutics.

The review process will determine whether the available evidence supports the proposed use of YUVEZZI for treating presbyopia in adults.

The company’s application is supported by the Phase 3 BRIO I and BRIO II studies, which demonstrated improvements in near vision following once-daily administration and provided safety and tolerability information from the clinical development program.

The regulatory assessment will be an important milestone in determining the product’s potential entry into the Canadian ophthalmic pharmaceutical market.

For Tenpoint Therapeutics, the submission reflects continued progress toward its objective of developing and commercializing treatments designed to improve vision in the aging eye.

With approximately 2 billion people affected by presbyopia worldwide, the condition represents a substantial global vision care need. The development of additional pharmaceutical treatment options could expand the approaches available to patients experiencing age-related near-vision impairment.

Through the Canadian NDS submission, Tenpoint Therapeutics is advancing YUVEZZI toward potential regulatory approval and broader international availability. If authorized, the once-daily combination eye drop could provide adults in Canada with an additional option for managing presbyopia and addressing the visual challenges associated with everyday activities.

About YUVEZZI™

YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily, dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a condition characterized by the gradual loss of close-up vision that typically begins around age 45.3,5

YUVEZZI combines two medicines that work together to improve close-up vision. Carbachol helps pupils get smaller (or “constrict”), making it easier to focus up close. Brimonidine helps keep pupils from getting too large (or “dilating”).

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter